Emmaus Life Sciences, Inc. announced that it has received Registration Approval from the Pharmaceutical and Herbal Medicines Registration and Control Administration (Drug and Food Control) of the Kuwaiti Ministry of Health granting marketing authorization for the commercial distribution and sale of Endari® in the country. Kuwait is the latest Gulf Cooperation Council country to grant full marketing approval for Endari® following approvals in the United Arab Emirates and the State of Qatar earlier this year. Endari® is approved in the U.S. and elsewhere to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

Endari® is available on an early access basis in Bahrain and the Kingdom of Saudi Arabia pending official notice of action on Emmaus's marketing authorization applications in those countries.